Provided by Tiger Trade Technology Pte. Ltd.

Chugai Pharmaceutical Co., Ltd.

58.61
-1.1175-1.87%
Volume:1.74K
Turnover:103.86K
Market Cap:96.41B
PE:43.70
High:61.10
Open:61.00
Low:58.60
Close:59.73
52wk High:72.30
52wk Low:38.76
Shares:1.65B
Float Shares:1.65B
Volume Ratio:2.33
T/O Rate:0.00%
Dividend:0.80
Dividend Rate:1.36%
EPS(TTM):1.34
EPS(LYR):1.40
ROE:22.10%
ROA:15.77%
PB:7.30
PE(LYR):41.76

Loading ...

Company Profile

Company Name:
Chugai Pharmaceutical Co., Ltd.
Exchange:
PINK LIMITED
Establishment Date:
1925
Employees:
5026
Office Location:
Nihonbashi Mitsui Tower,Reception12F,1-1 Nihonbashi-Muromachi 2-chome,Chuo,Tokyo,Japan
Zip Code:
103-8324
Fax:
81 3 3281 6607
Introduction:
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.